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Background. Studies have suggested that patients with schizophrenia are impaired at recognizing emotions.
Recently, it has been shown that the neuropeptide oxytocin can have beneﬁcial eﬀects on social behaviors.
Method. To examine emotion recognition deﬁcits in patients and see whether oxytocin could improve these deﬁcits,
we carried out two experiments. In the ﬁrst experiment we recruited 30 patients with schizophrenia and 29 age- and
IQ-matched control subjects, and gave them an emotion recognition task. Following this, we carried out a second
experiment in which we recruited 21 patients with schizophrenia for a double-blind, placebo-controlled cross-over
study of the eﬀects of oxytocin on the same emotion recognition task.
Results. In the ﬁrst experiment we found that patients with schizophrenia had a deﬁcit relative to controls in
recognizing emotions. In the second experiment we found that administration of oxytocin improved the ability of
patients to recognize emotions. The improvement was consistent and occurred for most emotions, and was present
whether patients were identifying morphed or non-morphed faces.
Conclusions. These data add to a growing literature showing beneﬁcial eﬀects of oxytocin on social–behavioral
tasks, as well as clinical symptoms.
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Introduction
Impairments in social functioning are common in
schizophrenia. Numerous studies have shown im-
paired perception of emotional expressions in schizo-
phrenia (Edwards et al. 2002; Tremeau, 2006) and
unaﬀected ﬁrst-degree relatives also seem to be im-
paired, albeit to a lesser extent (Bediou et al. 2007).
Further, diﬃculties in classifying emotions have been
shown to contribute to social-skill deﬁcits (Morris et al.
2009).
Recent results have suggested that the nonapeptide
oxytocin can improve emotion recognition in patients
with autism spectrum disorders (ASDs; Guastella
et al. 2010). Related studies in this patient group have
also shown that oxytocin increases social interactions.
Speciﬁcally, when patients with ASD played a game
in which they could choose to throw a ball to one of
three players, treatment with oxytocin increased
interactions with players that were more likely to
throw the ball back to the patient (Andari et al. 2010).
In the same study oxytocin treatment also increased
ratings of trust and preference for the most interactive
player. Additional studies have also shown that
oxytocin increases saccades to the eye region when
patients with ASD (Andari et al. 2010) or healthy sub-
jects (Guastella et al. 2008a) viewed pictures of faces.
Imaging data has also shown that the increased sac-
cades to the eye region on oxytocin are likely driven by
amygdala–brain stem interactions (Gamer et al. 2010).
In the current experiments we hypothesized that:
(1) patients with schizophrenia would have a deﬁcit
relative to a control group on recognizing emotions;
and (2) oxytocin could ameliorate some of this deﬁcit.
To examine these hypotheses we carried out two
experiments. In the ﬁrst, a group of patients with
schizophrenia was compared with a group of control
participants on an emotion recognition task and we
found that patients had a deﬁcit in emotion recog-
nition. In the second experiment the eﬀects of oxytocin
on the performance of the same emotion recognition
task were examined in a group of patients with
schizophrenia. We found that administration of
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tients to identify the emotions in the task.
Method
Patients
All subjects were recruited from the out-patient de-
partment of South London and Maudsley NHS Trust
(London, UK). Two groups of patients and one group
of controls were recruited for separate experiments.
The ﬁrst experiment compared patients with controls
on an emotion discrimination task, and the second
experiment examined the eﬀects of oxytocin in a pa-
tient group (partially overlapping with the ﬁrst patient
group) on the same task. Most aspects of the protocol
were the same for the two experiments. Speciﬁc details
are given for the diﬀerences. For experiment 1, in
which patients were compared with a matched control
group on the emotion discrimination task, we re-
cruited 30 individuals (of which 24 were male) who
met the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) criteria for schizo-
phrenia (Table 1). In addition to their anti-psychotics
(Table 1), one of these individuals was taking lithium
and one zopiclone, which is a sleep aid. For exper-
iment 2, in which patients with schizophrenia were
studied on oxytocin and placebo on the emotion dis-
crimination task, we recruited 21 individuals (all were
male) who met DSM-IV criteria for schizophrenia
(Table 2). In addition to their anti-psychotics, two of
these patients were additionally on selective serotonin
reuptake inhibitors (SSRIs), one on a benzodiazepine,
one on an anti-cholinergic and one on a vesicular
monoamine transport (VMAT) inhibitor, which re-
duces available dopamine stores. Chlorpromazine
equivalent units were calculated according to pub-
lished tables (Woods, 2003) and the British National
Formulary (BNF 54; British Medical Association & the
Royal Pharmaceutical Society of Great Britain). All
patients were assessed by an experienced clinician
who determined whether they met the DSM-IV cri-
teria for schizophrenia and made the diagnosis.
Patients also underwent a Positive and Negative
Symptom Scale (PANSS) interview (Kay et al. 1987) on
the ﬁrst day of testing in each experiment. The PANSS
is a clinical interview which assesses the patients on
seven aspects of positive symptoms, seven aspects of
negative symptoms and 16 aspects of general symp-
tomatology. All participants in the oxytocin study
were male because oxytocin can induce uterine con-
tractions in pregnant females and therefore it poses
increased risks. Of the participants in the oxytocin
group, 11 had participated in the original study
Table 1. Participant demographic information for comparison between patients and
controls
Patient group Control group
Subjects, n 30 29
Males, n 24 18
Females, n 61 1
Age, years 40.29 (1.5) 34.34 (2.43)
IQ 104.6 (2.40) 112.8 (2.51)
PANSS scores
Positive 12.4 (0.98)
Negative 13.6 (1.27)
General 24.0 (1.41)
Total 50.8 (3.22)
Medication, mg chlorpromazine
equivalents per day
301 (46.2)
Antipsychotics, n
Typical 3 (clopixol, pirportil)
Atypical 25 (olanzapine, risperidone,
clozapine, quetiapine,
amisulpride, risperdal consta,
aripiprazole)
None 2
Data are given as mean (standard error of the mean) or as number of subjects.
IQ, Intelligence quotient; PANSS, Positive and Negative Symptom Scale.
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the two experiments in this group of eleven patients
was on average 21.6 months, with a minimum of
10 months. A t test on overall performance in the
oxytocin experiment, between the group of patients
that had participated in the original study and the
patients newly recruited for the oxytocin study,
showed no diﬀerence (p=0.774). We also compared
performance on the task in the group that was tested
twice, by correlating performance across conditions,
within subject. For this we used only the placebo data
from the second experiment. The correlation between
sessions was 0.57 (S.D. 0.35). Most of the correlations
were relatively high. However, two of the patients had
low correlations (x0.01 and x0.08).
All subjects provided written consent. Standard
consent and safety reporting procedures were fol-
lowed, and ethical approval was obtained from the
South London and Maudsley, Institute of Psychiatry,
King’s College London research ethics committee.
Patients were stable on treatment with antipsychotic
medication (see Tables 1 and 2 for type of medication).
Those with dual diagnoses and drug and alcohol
problems were excluded from the study. In the oxy-
tocin study, participants were also excluded if they
had high blood pressure (greater than 140/90 mmHg),
heart problems or any major non-psychiatric illness or
hospitalization in the last year.
Control group
For the study which compared patients with controls,
a group of 29 control participants was recruited
(Table 1). These were age, gender and IQ matched to
the patient group. IQ was estimated from errors in the
National Adult Reading Test. Inclusion criteria stipu-
lated no psychiatric history and no history of drug or
alcohol problems.
Oxytocin administration
The oxytocin study was carried out using a double-
blind placebo-controlled cross-over design, so neither
the individual administering the drug nor the partici-
pant knew if they were receiving the drug or placebo.
Each participant completed two sessions of testing
separated by 7 or 8 days (mean=7.33, S.E.M.=0.10
days). All recruited participants performed the task in
both sessions and none of the participants dropped
out. The procedure was the same for each session.
Upon arrival, the participant self-administered a nasal
spray consisting of either 24 IU oxytocin (Syntocinon,
Novartis) or saline placebo. This is similar to the dose
which has been used in previous studies which have
shown eﬀects (Kirsch et al. 2005; Guastella et al. 2008b;
Savaskan et al. 2008; Rimmele et al. 2009; Evans et al.
2010). Each participant received both oxytocin and
placebo and the order in which they received them
was randomized. Of 21 subjects, 11 received placebo
ﬁrst and 10 received oxytocin ﬁrst. Of the 11 partici-
pants that had been involved in the original exper-
iment comparing controls and patients on emotion
recognition, six received placebo ﬁrst and ﬁve re-
ceived oxytocin ﬁrst.
Following administration, behavioral testing com-
menced after a 50-min delay. It has been shown that
vasopressin, which is closely related to oxytocin,
reaches peak eﬀects in 30–50 min when administered
transnasally (Born et al. 2002), and a 50-min delay be-
tween drug administration and the start of testing has
been used in previous studies with oxytocin (Kirsch
et al. 2005; Domes et al. 2007b; Evans et al. 2010;
Fischer-Shofty et al. 2010).
To examine non-speciﬁc eﬀects of the drug on
mood, participants completed a questionnaire just be-
fore testing began, 50 min after drug delivery, on both
the drug and placebo visit. The questionnaire used
was the Brief Mood Inventory Scale (Mayer &
Gaschke, 1988). Participants rated 16 dimensions of
mood on a scale of 1 to 4, followed by overall mood on
a scale of x10 to +10. There was no eﬀect of the drug
on the patients’ pleasant/unpleasant ratings score
Table 2. Participant demographic information for oxytocin study
Patients
Subjects, n 21
Males, n 21
Females, n 0
Age, years 38.2 (1.8)
IQ 100.8 (2.1)
PANSS scores
Positive 14.1 (1.5)
Negative 16.4 (0.9)
General 28.3 (1.5)
Total 58.9 (3.3)
Medication,
mg chlorpromazine
equivalents per day
512 (75.7)
Antipsychotics, n
Typical 2 (clopixol and
zuclopentixol decanoate)
Atypical 19 (olanzapine, clozapine,
risperidone, amisulpride
and aripiprazole)
Data are given as mean (standard error of the mean) or as
number of subjects.
IQ, Intelligence quotient; PANSS, Positive and Negative
Symptom Scale.
Schizophrenia, oxytocin and emotions 261[t(20)=1.24, p=0.228] or on overall mood [t(20)=1.18,
p=0.253], consistent with several previous studies in
healthy participants (Kirsch et al. 2005; Di Simplicio
et al. 2009; Evans et al. 2010; Fischer-Shofty et al. 2010;
Marsh et al. 2010). Safety reporting procedures were in
accordance with local research and development
guidelines. Participants were monitored closely fol-
lowing spray delivery. No adverse events occurred.
Task
Participants in both experiments carried out the hexa-
gon emotion discrimination task, used to characterize
emotion recognition (Calder et al. 1996). They received
instructions on-screen prior to the task. The instruc-
tions were as follows. ‘You will see a face presented
on the screen. You are to indicate which word best
describes the emotion in the face. Please press keys 1
to 6 to choose the emotions.’ On each trial, a face was
presented for 1000 ms. This was followed by a choice
screen which presented the options with a number
next to each emotion name. Participants used the
keyboard to indicate their choice. The faces were
drawn from the Ekman series (Ekman & Friesen,
1971). Both unmorphed and morphed (70%/30%) fa-
ces were used. There were a total of 192 trials, of which
half were morphed. Four diﬀerent identities (IDs)
were used [two male (IDs 2 and 10) and two female
(IDs 9 and 11) from the Ekman set] and each image
was shown four times, not sequentially. Stimulus or-
der was randomized across all conditions including
morphed and unmorphed. Morphs were between the
following pairs of emotions: happiness–surprise;
surprise–fear; fear–sadness; sadness–disgust; disgust–
anger; anger–happiness. Morphs between these emo-
tions are used as these are the emotions which are
most often confused when emotions in unmorphed
faces are identiﬁed (Calder et al. 1996). The morphs
were generated using Abrosoft Fantamorph software
(Abrosoft, USA). To morph the images, corresponding
points are ﬁrst deﬁned on the two images between
which the morphs would be produced. The points
were located on the eyes, nose, mouth, chin and fore-
head. The software then stretches the images, as if they
were printed on a sheet of rubber, such that points on
the morphed image lie between the points on each of
the unmorphed images, with the distance given by the
morph fraction. For example, for a 70% fearful/30%
sad morph, the points would be stretched so they
would lie 70% of the way to the fearful face, from
the sad face, and correspondingly 30% of the way to
the sad face, from the fearful face. The pixel intensity
values were then blended between the two stretched
faces, using the appropriate weight, for example, a
70% weight on the fearful and a 30% weight on the
sad pixel intensities. Additional details of the pro-
cedure have been given previously (Calder et al. 1996).
Data analysis
Trials involving morphed and unmorphed faces were
analysed separately. Percentage correct was calculated
for each of the six emotions presented, under the
morphed and unmorphed conditions. For morphed
trials, the majority emotion present was considered
the correct choice. These values were then entered as
the dependent variable in a three-way mixed-eﬀects
analysis of variance (ANOVA) with morph, emotion
and drug as main eﬀects for the oxytocin study, or
morph, emotion and group as main eﬀects for the
control study. Thus, the eﬀects on all emotions were
assessed in an omnibus ANOVA. Order of drug versus
placebo session was added as a factor in the analysis of
the oxytocin data. ANOVA assumptions were checked
by examining residuals for normality. Post-hoc t tests
were not corrected for multiple comparisons. This al-
lows for more direct comparison with other studies
which may use fewer emotions.
Results
Experiment 1: comparison of patients and controls
In experiment 1, when the patient group was com-
pared with a matched control group, the patients were
less accurate than controls in both morphed and un-
morphed conditions and the performance of both
groups was worse in the morphed condition
(Fig. 1a, b). There were main eﬀects of group [F(1,57)=
14.41, p<0.001], emotion [F(5,285)=40.95, p<0.001]
and morphing [F(1,342)=125.25, p<0.001], but
neither the emotionrgroup [F(1,285)=1.36, p=0.239]
nor the grouprmorphing [F(1,342)=1.62, p=0.204]
interaction was signiﬁcant. Therefore, lowering the
emotional intensity by using morphed stimuli did re-
duce performance, but there was no diﬀerential
impairment between patients and controls. When in-
dividual emotions were compared separately between
groups, there were signiﬁcant diﬀerences (uncorrected
t tests, p<0.05) in fear, happiness and surprise in both
the morphed and unmorphed conditions (Table 3).
To control for IQ-related performance eﬀects, we
examined correlations between IQ scores and overall
accuracy on morphed and unmorphed trials com-
bined. In patients there was no signiﬁcant correlation
[R(29)=0.185, p=0.327]. However in controls there
was a signiﬁcant correlation [R(28)=0.619, p<0.001].
IQ scores for all subjects were then entered in the
ANOVA as a covariate to conﬁrm that variation in
IQ could not account for the group diﬀerences. The
main eﬀect of group was still present [F(1,57)=8.88,
262 B. B. Averbeck et al.p=0.006] with IQ-related variance removed. A similar
analysis was performed to account for medication
status. There was no signiﬁcant correlation between
medication status in chlorpromazine equivalent units
and overall performance in the patient group [R(23)=
0.067, p=0.757].
Experiment 2: eﬀects of oxytocin in patients
Subsequent to the ﬁrst experiment showing decreased
performance in patients relative to matched controls,
we carried out a separate experiment in a patient
group to examine the eﬀects of oxytocin on emotion
discrimination. Analysis of the fraction correct data of
each participant, comparing oxytocin with placebo,
morphed with non-morphed trials for each emotion
(Fig. 1c,d) showed main eﬀects of drug [F(1,264)=
7.74, p=0.006], morph [F(1,322)=22.31, p<0.001] and
emotion [F(5,100)=35.42, p<0.001]. There were no
signiﬁcant interactions (p>0.447). Although the over-
all performance was generally improved on oxytocin,
none of the individual emotions showed a signiﬁcant
diﬀerence (t test, p<0.05), although fear showed a
trend in the unmorphed condition (Table 4).
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Fig. 1. Fraction correct for each emotion. (a) Patients v. controls unmorphed faces. (b) Patients v. controls morphed faces.
(c) Patients on v. oﬀ oxytocin unmorphed faces. (d) Patients on v. oﬀ oxytocin morphed faces. Data are means, with standard
errors of the mean computed across participants represented by vertical bars.
Table 3. Statistics on individual emotions for comparison of
patients and controls
Emotion Unmorphed faces Morphed faces
Anger 1.99 (0.051) 1.78 (0.080)
Disgust 1.27 (0.211) 0.94 (0.348)
Fear 2.79 (0.007) 2.68 (0.010)
Happiness 2.35 (0.022) 2.40 (0.020)
Sadness 1.32 (0.192) 0.75 (0.454)
Surprise 3.99 (0.002) 3.34 (0.002)
Data are given as t statistic (p).
Table 4. Statistics on individual emotions for eﬀects of oxytocin
in patients
Emotion Unmorphed faces Morphed faces
Anger 0.84 (0.410) 0.80 (0.435)
Disgust 0.60 (0.553) 0.29 (0.78)
Fear 2.00 (0.059) 0.51 (0.612)
Happiness 0.76 (0.456) 1.30 (0.208)
Sadness 1.57 (0.132) 1.76 (0.093)
Surprise 0.33 (0.748) 0.00 (1.00)
Data are given as t statistic (p).
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ﬁrst day of testing, we could not examine changes in
PANSS scores with the drug. However, we did corre-
late the improvement in emotion recognition with
positive, negative and general PANSS scores, across
subjects. None of the correlations was signiﬁcant,
however (p>0.10).
In the ﬁnal analysis we compared the performance
of the patients from the second experiment on oxy-
tocin with the performance of the control group in the
ﬁrst experiment, to see the eﬀect of oxytocin on the
group diﬀerence. Performance of the patients on oxy-
tocin was, however, still lower than the performance
of the control group, as there was still a main eﬀect of
group [F(1,48)=26.7, p<0.001]. The control group
performed at 72% correct, the patient group oﬀ oxy-
tocin in the second experiment at 54% correct and the
patient group on oxytocin at 58% correct. Thus, oxy-
tocin made up 22% of the diﬀerence in performance.
Discussion
In the ﬁrst experiment, we found that patients with
schizophrenia were less accurate at identifying emo-
tions than a group of matched controls. This is con-
sistent with several previous studies which have
shown that patients with schizophrenia (Edwards et al.
2002; Kohler et al. 2003; Bediou et al. 2005; Tremeau,
2006; Derntl et al. 2009) and their ﬁrst-degree relatives
(Bediou et al. 2007) have a deﬁcit in identifying emo-
tions. Other studies have also suggested that this
deﬁcit may contribute to deﬁcits in social skills (Morris
et al. 2009). We did not ﬁnd, in our study, that there
were emotionrgroup or grouprmorphing interac-
tions. Thus, patients were generally worse at re-
cognizing emotions. Future studies could utilize a test
of face recognition, for example, the Benton Facial
Recognition Test (Benton et al. 1994) to examine whe-
ther the eﬀects were speciﬁc to identifying emotions,
or more general deﬁcits in processing face infor-
mation. Most of our patients were also on anti-
psychotic medication, and it is currently not clear the
extent to which medication might contribute to deﬁcits
in emotion recognition. In the second experiment we
found that administration of the nonapeptide oxytocin
signiﬁcantly improved the ability of patients with
schizophrenia to identify the basic emotions. Emotion
identiﬁcation is a well-established issue that may have
general consequences for social behavior in patients
and oxytocin may help to ameliorate this deﬁcit.
Eﬀects in our task were relatively modest, however,
and the sample size was also relatively small.
Additional experiments will help to substantiate these
eﬀects.
There has been considerable interest in the social
eﬀects of the neuropeptide oxytocin. Oxytocin is pro-
duced in the hypothalamus and it is released into
the bloodstream where it mediates contractions of
the uterus during parturition as well as milk release
during breast feeding (Burbach et al. 2006). However,
oxytocin is also released into the central nervous sys-
tem (Veening et al. 2010), where it can bond to oxytocin
receptors in various brain areas (Schorscher-Petcu
et al. 2009). Work in rodents has shown important
eﬀects of oxytocin on pair bonding and maternal
behaviors (Pedersen et al. 1982; Fahrbach et al. 1985;
Williams et al. 1994; Cho et al. 1999; Lim & Young,
2006).
The eﬀects of oxytocin on social behaviors in human
subjects have also been examined recently. These
studies have found that oxytocin can improve emotion
identiﬁcation in the reading the mind from the eyes
task, in healthy human participants (Domes et al.
2007b). This improvement in performance may come
from the fact that oxytocin increases saccades to the
eye region (Guastella et al. 2008a), an eﬀect mediated
by interactions between the amygdala and brain stem
regions involved in saccade generation (Gamer et al.
2010). Other work has shown that oxytocin can de-
crease aversion to angry faces in decision-making
tasks (Evans et al. 2010), an eﬀect which might be
mediated by decreased amygdala responses to angry
faces (Kirsch et al. 2005), although other work has
shown that oxytocin decreases amygdala responses to
other emotions as well (Domes et al. 2007a). Related to
this, oxytocin has also been shown to decrease nega-
tive aﬀective evaluation of faces that have been nega-
tively conditioned with shock, an eﬀect also mediated
by the amygdala (Petrovic et al. 2008). One limitation
of our second study utilizing oxytocin is that only
male participants were tested, as is the case in most
studies of oxytocin. This is an important limitation that
should be examined in future studies as it has been
shown that oxytocin aﬀects processing of emotional
faces diﬀerently in males and females (Domes et al.
2010).
Interest in oxytocin has also extended to clinical
populations characterized by some degree of social
deﬁcits, including ASD and schizophrenia. Work in
these groups has shown that oxytocin can improve
emotion recognition deﬁcits in patients with ASD
(Guastella et al. 2010). It also increases the incidence
with which patients with ASD choose to interact with
highly social individuals in games, and increases rat-
ings of trust and preference for these highly social in-
dividuals, by the participants with ASD (Andari et al.
2010). Thus, oxytocin appears to improve some basic
social deﬁcits in ASD. Although rodent studies have
generally found that oxytocin’s eﬀects are speciﬁc to
264 B. B. Averbeck et al.social function (Lim & Young, 2006), the extent to
which oxytocin might improve general cognitive
function, as opposed to speciﬁcally social function, is
an open question in human studies. Modaﬁnil, for
example, which aﬀects alertness, has been shown to
improve the recognition of emotions (Scoriels et al.
2011).
Interest in oxytocin in schizophrenia is just begin-
ning to emerge. Recent studies have shown improve-
ments in clinical symptoms, including both positive
and negative symptoms, with oxytocin administration
(Feifel et al. 2010; Rubin et al. 2010). Complementing
this, our results suggest that oxytocin can have
beneﬁcial eﬀects on emotion recognition, a well-
documented deﬁcit in this clinical population, which
may have an impact on symptoms in the longer term,
as diﬀerences were only evident after 3 weeks of
treatment (Feifel et al. 2010), as well as contributing to
better social functioning in the patients. Our study also
demonstrates acute improvements in emotion recog-
nition. This oﬀers the potential in the future of in-
tegrating oxytocin treatment with psychological
therapy using the window of opportunity created by
the acute oxytocin eﬀects.
Acknowledgements
The authors wish to thank all the volunteers who
participated in this study. This work was supported
by a Medical Research Council (MRC) project grant to
S.S.S. and this work was also supported in part by the
Intramural Program of the National Institutes of
Health (NIH), National Institute of Mental Health.
Declaration of Interest
S.S.S. has received compensation from GlaxoSmith-
Kline over the past 3 years.
References
Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M,
Sirigu A (2010). Promoting social behavior with oxytocin
in high-functioning autism spectrum disorders. Proceedings
of the National Academy of Sciences USA 107, 4389–4394.
Bediou B, Asri F, Brunelin J, Krolak-Salmon P, D’Amato T,
Saoud M, Tazi I (2007). Emotion recognition and genetic
vulnerability to schizophrenia. British Journal of Psychiatry
191, 126–130.
Bediou B, Franck N, Saoud M, Baudouin JY, Tiberghien G,
Dale ´ry J, d’Amato T (2005). Eﬀects of emotion and identity
on facial aﬀect processing in schizophrenia. Psychiatry
Research 133, 149–157.
Benton AL, Sivan AB, Hamsher K, Varney NR, Spreen O
(1994). Contributions to Neuropsychological Assessment.
Oxford University Press: New York.
Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL
(2002). Sniﬃng neuropeptides: a transnasal approach to
the human brain. Nature Neuroscience 5, 514–516.
British Medical Association & the Royal Pharmaceutical
Society of Great Britain (2007). British National Formulary:
54 (ed. D. Mehta). BMJ Publishing Group: London.
Burbach JP, Young LJ, Russell J (2006). Oxytocin: synthesis,
secretion and reproductive functions. In Knobil and Neill’s
Physiology of Reproduction, 3rd edn (ed. J. D. Neill),
pp. 3055–3128. Elsevier: London.
Calder AJ, Young AW, Rowland D, Perrett DI, Hodges JR,
Etcoﬀ NL (1996). Facial emotion recognition after bilateral
amygdala damage: diﬀerentially severe impairment of
fear. Cognitive Neuropsychology 13, 699–745.
Cho MM, DeVries AC, Williams JR, Carter CS (1999). The
eﬀects of oxytocin and vasopressin on partner preferences
in male and female prairie voles (Microtus ochrogaster).
Behavioral Neuroscience 113, 1071–1079.
Derntl B, Finkelmeyer A, Toygar TK, Hulsmann A,
Schneider F, Falkenberg DI, Habel U (2009). Generalized
deﬁcit in all core components of empathy in schizophrenia.
Schizophrenia Research 108, 197–206.
Di Simplicio M, Massey-Chase R, Cowen PJ, Harmer CJ
(2009). Oxytocin enhances processing of positive versus
negative emotional information in healthy male
volunteers. Journal of Psychopharmacology 23, 241–248.
Domes G, Heinrichs M, Gla ¨scher J, Bu ¨chel C, Braus DF,
Herpertz SC (2007a). Oxytocin attenuates amygdala
responses to emotional faces regardless of valence.
Biological Psychiatry 62, 1187–1190.
Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC
(2007b). Oxytocin improves ‘mind-reading’ in humans.
Biological Psychiatry 61, 731–733.
Domes G, Lischke A, Berger C, Grossmann A, Hauenstein
K, Heinrichs M, Herpertz SC (2010). Eﬀects of intranasal
oxytocin on emotional face processing in women.
Psychoneuroendocrinology 35, 83–93.
Edwards J, Jackson HJ, Pattison PE (2002). Emotion
recognition via facial expression and aﬀective prosody in
schizophrenia: a methodological review. Clinical
Psychology Review 22, 789–832.
Ekman P, Friesen WV (1971). Constants across cultures in
the face and emotion. Journal of Personality and Social
Psychology 17, 124–129.
Evans S, Shergill SS, Averbeck BB (2010). Oxytocin
decreases aversion to angry faces in an associative learning
task. Neuropsychopharmacology 35, 2502–2509.
Fahrbach SE, Morrell JI, Pfaﬀ DW (1985). Possible role for
endogenous oxytocin in estrogen-facilitated maternal
behavior in rats. Neuroendocrinology 40, 526–532.
Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H,
Galangue B, Minassian A, Becker O, Cooper J, Perry W,
Lefebvre M, Gonzales J, Hadley A (2010). Adjunctive
intranasal oxytocin reduces symptoms in schizophrenia
patients. Biological Psychiatry 68, 678–680.
Fischer-Shofty M, Shamay-Tsoory SG, Harari H, Levkovitz
Y (2010). The eﬀect of intranasal administration of oxytocin
on fear recognition. Neuropsychologia 48, 179–184.
Gamer M, Zurowski B, Buchel C (2010). Diﬀerent amygdala
subregions mediate valence-related and attentional eﬀects
Schizophrenia, oxytocin and emotions 265of oxytocin in humans. Proceedings of the National Academy
of Sciences USA 107, 9400–9405.
Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ,
Lambert TJ, Hickie IB (2010). Intranasal oxytocin
improves emotion recognition for youth with autism
spectrum disorders. Biological Psychiatry 67, 692–694.
Guastella AJ, Mitchell PB, Dadds MR (2008a). Oxytocin
increases gaze to the eye region of human faces. Biological
Psychiatry 63, 3–5.
Guastella AJ, Mitchell PB, Mathews F (2008b). Oxytocin
enhances the encoding of positive social memories in
humans. Biological Psychiatry 64, 256–258.
Kay SR, Fiszbein A, Opler LA (1987). The positive and
negative syndrome scale (PANSS) for schizophrenia.
Schizophrenia Bulletin 13, 261–276.
Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S,
Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A
(2005). Oxytocin modulates neural circuitry for social
cognition and fear in humans. Journal of Neuroscience 25,
11489–11493.
Kohler CG, Turner TH, Bilker WB, Brensinger CM,
Siegel SJ, Kanes SJ, Gur RE, Gur RC (2003). Facial
emotion recognition in schizophrenia: intensity eﬀects
and error pattern. American Journal of Psychiatry 160,
1768–1774.
Lim MM, Young LJ (2006). Neuropeptidergic regulation of
aﬃliative behavior and social bonding in animals.
Hormones and Behavior 50, 506–517.
Marsh AA, Yu HH, Pine DS, Blair RJ (2010). Oxytocin
improves speciﬁc recognition of positive facial expressions.
Psychopharmacology (Berlin) 209, 225–232.
Mayer JD, Gaschke YN (1988). The experience and
meta-experience of mood. Journal of Personality and Social
Psychology 55, 102–111.
Morris RW, Weickert CS, Loughland CM (2009). Emotional
face processing in schizophrenia. Current Opinion in
Psychiatry 22, 140–146.
Pedersen CA, Ascher JA, Monroe YL, Prange Jr. AJ (1982).
Oxytocin induces maternal behavior in virgin female rats.
Science 216, 648–650.
Petrovic P, Kalisch R, Singer T, Dolan RJ (2008). Oxytocin
attenuates aﬀective evaluations of conditioned faces and
amygdala activity. Journal of Neuroscience 28, 6607–6615.
Rimmele U, Hediger K, Heinrichs M, Klaver P (2009).
Oxytocin makes a face in memory familiar. Journal of
Neuroscience 29, 38–42.
Rubin LH, Carter CS, Drogos L, Pournajaﬁ-Nazarloo H,
Sweeney JA, Maki PM (2010). Peripheral oxytocin is
associated with reduced symptom severity in
schizophrenia. Schizophrenia Research 124, 13–21.
Savaskan E, Ehrhardt R, Schulz A, Walter M,
Schachinger H (2008). Post-learning intranasal oxytocin
modulates human memory for facial identity.
Psychoneuroendocrinology 33, 368–374.
Schorscher-Petcu A, Dupre ´ A, Tribollet E (2009).
Distribution of vasopressin and oxytocin binding sites in
the brain and upper spinal cord of the common marmoset.
Neuroscience Letters 461, 217–222.
Scoriels L, Barnett JH, Murray GK, Cherukuru S, Fielding
M, Cheng F, Lennox BR, Sahakian BJ, Jones PB (2011).
Eﬀects of modaﬁnil on emotional processing in ﬁrst
episode psychosis. Biological Psychiatry 69, 457–464.
Tremeau F (2006). A review of emotion deﬁcits in
schizophrenia. Dialogues in Clinical Neuroscience 8, 59–70.
Veening JG, de Jong T, Barendregt HP (2010). Oxytocin-
messages via the cerebrospinal ﬂuid: behavioral eﬀects;
a review. Physiology and Behavior 101, 193–210.
Williams JR, Insel TR, Harbaugh CR, Carter CS (1994).
Oxytocin administered centrally facilitates formation of
a partner preference in female prairie voles (Microtus
ochrogaster). Journal of Neuroendocrinology 6, 247–250.
Woods SW (2003). Chlorpromazine equivalent doses for the
newer atypical antipsychotics. Journal of Clinical Psychiatry
64, 663–667.
266 B. B. Averbeck et al.